Harold Bernstein Sells $381K of Maze Therapeutics Inc (MAZE) — SEC Form 4, Jun 03, 2026
Open-Market Net Sale · SEC Form 4
−$381,112
10b5-1 Plan
Equity Position
14.9K sh
14,853 → 14,853
Filing Lag
2 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Harold Bernstein CIK 0002050172 |
President
|
Harold Bernstein at Maze Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$9,456,378
More from this insider at Maze Therapeutics Inc
| 2026-10-02 | Sell | -$434,743 | View |
| 2026-09-08 | Sell | -$254,502 | View |
| 2026-09-04 | Sell | -$270,111 | View |
| 2026-09-03 | Sell | -$425,512 | View |
| 2026-08-14 | Sell | -$445,621 | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common StockF1 | 2026-06-01 | M - Exercise 10b5-1 | 14,853 A | $10.42 | +$154,768 | 14,853 | Direct |
| Common StockF1F2 | 2026-06-01 | S - Sale 10b5-1 | 13,253 D | $25.57 | -$338,940 | 1,600 | Direct |
| Common StockF1F3 | 2026-06-01 | S - Sale 10b5-1 | 1,600 D | $26.36 | -$42,172 | 0 | Direct |
Derivative Securities Transactions
Footnotes (4)
- F1
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025. Show more
- F2
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.16 to $26.10 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Show more
- F3
- The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.16 to $26.53 per share, inclusive. Show more
- F4
- The option vested as to 1/4th of the total award on October 3, 2023, and thereafter vested or vests as to 1/48th of the total award on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Show more
Related filings at Maze Therapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
161
institutional managers reporting a position
Largest by reported value
- Frazier Life Sciences Management, L.P. $150M
- Trv Gp Iv, Llc $134M
- Arch Venture Management, Llc $123M
5%+ Holders · 13D/G
6 filers
Other insiders at Maze Therapeutics Inc
-
Jason Coloma V -$1.04M
-
Atul Dandekar -$241K
-
Jason Coloma V -$932K
-
Atul Dandekar -$203K
-
Phillips Courtney -$105K
GET /v1/forms/4/0002050172-26-000023
API docs
View Original SEC Filing